Exane Derivatives Takeda Pharmaceutical CO LTD Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
Shares
4 transactions
Others Institutions Holding TAK
# of Institutions
320Shares Held
70.4MCall Options Held
939KPut Options Held
233K-
Capital Research Global Investors Los Angeles, CA13.1MShares$182 Million0.04% of portfolio
-
Mondrian Investment Partners LTD London, X07.74MShares$107 Million1.74% of portfolio
-
Morgan Stanley New York, NY4.99MShares$69.1 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.35MShares$60.2 Million0.03% of portfolio
-
Goldman Sachs Group Inc New York, NY3.72MShares$51.5 Million0.01% of portfolio
About TAKEDA PHARMACEUTICAL CO LTD
- Ticker TAK
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 3,109,050,112
- Market Cap $43.1B
- Description
- Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived t...